Qsymia (Phentermine-topiramate) to Reduce Binge Eating/Purging in Patients With Bulimia Nervosa and Binge Eating Disorder
Phase of Trial: Phase I
Latest Information Update: 02 Aug 2018
At a glance
- Drugs Phentermine/topiramate (Primary)
- Indications Binge-eating disorder; Bulimia nervosa
- Focus Therapeutic Use
- 04 Jul 2018 New trial record
- 09 May 2018 Primary endpoint (Objective binge eating days (OBE days)/4 weeks: Phentermine/topiramate ER versus Placebo) has been met, according to results presented at the 171st Annual Meeting of the American Psychiatric Association.
- 09 May 2018 Results presented at the 171st Annual Meeting of the American Psychiatric Association.